Lakewood-Amedex Biotherapeutics Inc. (LABT)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.96M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About LABT
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of ... [Read more]
News
Lakewood-Amedex Biotherapeutics, Biotech Developing Novel Locally Delivered Antimicrobials for Resistant Infections and Chronic Wounds, Files for Nasdaq Capital Market IPO
Lakewood-Amedex Biotherapeutics filed an S-1 to list its common stock on the Nasdaq Capital Market under the ticker LABT via a direct listing.
Lakewood-Amedex Biotherapeutics IPO Registration Document (S-1)
Lakewood-Amedex Biotherapeutics has filed to go public with an IPO on the NASDAQ
Micro-cap biotech Lakewood-Amedex Biotherapeutics files for a Nasdaq direct listing
Lakewood-Amedex Biotherapeutics, which is developing a topical antimicrobial treatment for drug-resistant infections, filed on Friday for a direct listing on the Nasdaq. The shares of common stock lis...